Suppression of Telomerase Activity and Cytokine Messenger RNA Levels in Acute Myelogenous Leukemia Cells in Vivo in Patients by Amifostine and Interleukin 4
2000
High
levels of telomerase activity and high rates of cell proliferation are
associated with a poor prognosis in acute myelogenous leukemia.
Furthermore, cytokine production by leukemia cells is believed to play
an important role in determining the proliferative characteristics of
leukemia. The in vivo effects of two noncytotoxic agents
on these parameters were determined in 33 acute myelogenous leukemia
patients. Three daily doses of interleukin (IL) 4 or a single dose of
amifostine reduced telomerase activity in the leukemia marrow cells in
7 of 9 and 11 of 13 patients, respectively. The administration of a
single dose of amifostine resulted in a reduction in tumor necrosis
factor α and IL-6 transcript levels in the marrow cells of 10 of 13
and 12 of 13 patients in which these transcripts were present. The
administration of only three doses of IL-4 or a single dose of
amifostine has a significant effect on leukemia cell parameters, which
are believed to have a significant impact on the in vivo
biology of the disease and on its response to remission induction
therapy.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
13
References
17
Citations
NaN
KQI